BFAI (5,6-benzofuranyl-2-aminoindane) is a drug of the 2-aminoindane group that acts as a serotonin releasing agent (SSRA) and produces entactogen effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.[1] The drug was patented by Matthew Baggott and Tactogen in 2022.[1]

See also

References

  1. ^ a b WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc. 
Allikas: https://en.wikipedia.org/wiki/BFAI
No tags for this post.